A recent study from the “Ludwig Institute for Cancer Research, University of California, San Diego, La Jolla, CA, USA” shows that “mTOR complex 2 controls glycolytic metabolism … through FoxO acetylation and upregulation of c-Myc.” This study was published in the 17 October 13′ issue of the Journal “Cell Metabolism” by Prof Mischel PS, Masui K and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for Human cancers: mTORC2 suppresses the expression of tumor suppressor p53 via up regulation of its target gene
This study suggests an miRNA-based anti-cancer therapy that targets Cancer metabolism. mTORC2, by increasing the expression of its target gene, it may decrease the expression of tumor suppressor p53. Thus, pharmacological formulations encompassing “mTORC2 inhibitors” may be used to inhibit cancer progression.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Molecular therapy for Human cancers: mTORC2 suppresses the expression of tumor suppressor p53 via up regulation of its target gene, 20/April/2014, 11.51 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at firstname.lastname@example.org
* Research cooperation
Undisclosed information: How mTORC2 attenuates the expression of tumor suppressor p53